SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* ...

Similar documents
MicroScan Microbiology Systems MORE CHOICES MORE ANSWERS. MicroScan GRAM NEGATIVE AND GRAM POSITIVE PANELS

EUCAST recommended strains for internal quality control

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

European Committee on Antimicrobial Susceptibility Testing

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

European Committee on Antimicrobial Susceptibility Testing

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

AMR Industry Alliance Antibiotic Discharge Targets

Antimicrobial Susceptibility Testing: Advanced Course

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

What s new in EUCAST methods?

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

2015 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report

Antimicrobial Susceptibility Testing: The Basics

EUCAST-and CLSI potency NEO-SENSITABS

January 2014 Vol. 34 No. 1

Intrinsic, implied and default resistance

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

Performance Information. Vet use only

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

Concise Antibiogram Toolkit Background

56 Clinical and Laboratory Standards Institute. All rights reserved.

January 2014 Vol. 34 No. 1

REVOLUTIONARY. MMinimum. BBiofilm EEradication Concentration. inimizing WE HAVE FOUND THE ANSWER.

Antimicrobial Susceptibility Patterns

Understanding the Hospital Antibiogram

British Society for Antimicrobial Chemotherapy

British Society for Antimicrobial Chemotherapy

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

GENERAL NOTES: 2016 site of infection type of organism location of the patient

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology

MASTDISCS AST. Leading the field with a complete solution for AST and Identification disc testing. Comprehensive range. Premium quality products

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges

2 New products for 2014

Main objectives of the EURL EQAS s

Recommendations to take it forward!

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

Antimicrobial susceptibility

- the details, where possible, of the antibiotic products these companies supply or have supplied.

Brief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents

Introduction. Antimicrobial Usage ESPAUR 2014 Previous data validation Quality Premiums Draft tool CDDFT Experience.

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Interpreting Microbiology reports for better Clinical Decisions Interpreting Antibiogrammes

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

CONTAGIOUS COMMENTS Department of Epidemiology

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

EARS Net Report, Quarter

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

BSAC standardized disc susceptibility testing method (version 8)

Background and Plan of Analysis

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

TABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

Antimicrobial Pharmacodynamics

Should we test Clostridium difficile for antimicrobial resistance? by author

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India

Penicillins - EUCAST clinical MIC breakpoints (version 1.3)

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Antibiotics.

Available online at ISSN No:

1 INTRODUCTION OBJECTIVES OUTLINE OF THE SALM/CAMP EQAS

Taiwan Surveillance of Antimicrobial Resistance (TSAR)

CAP Laboratory Improvement Programs. Performance Accuracy of Antibacterial and Antifungal Susceptibility Test Methods

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

* gender factor (male=1, female=0.85)

Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,

RCH antibiotic susceptibility data

Vibrio vulnificus. Vibrio vulnificus V. vulnificus. pectinata japonica)

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

This document is protected by international copyright laws.

HUSRES Annual Report 2007 Martti Vaara.

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia

Surveillance for antimicrobial resistance in enteric bacteria in Australian pigs and chickens

microbiology testing services

ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat

EARS-Net Belgium Data call for 2016: Instructions for participating laboratories, including data definition. (version 4, 20/3/2017)

Michael Hombach*, Guido V. Bloemberg and Erik C. Böttger

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

ADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao

ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014

What is new in 2011: Methods and breakpoints in relation to subcommittees and expert groups. by author. Gunnar Kahlmeter, Derek Brown

Outline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory

Antibiotic Updates: Part II

University Ss Cyril and Methodius in Skopje Faculty of veterinary medicine-skopje

Transcription:

SMART WORKFLOW SOLUTIONS Introducing DxM MicroScan WalkAway System* The next-generation MicroScan WalkAway System combines proven technology and reliability with enhanced ease-of-use features to streamline workflows and improve productivity.... Continuous reagent monitoring technology provides enhanced liquid level sensing Easy-to-view external LED indicators show status at a glance Quick bottle release simplifies reagent maintenance Integrated reliability improvements maximize uptime * In development, pending CE compliance; not available for in vitro diagnostic use. Please contact your sales representative for more information.

COMING SOON FROM BECKMAN COULTER New MicroScan Gram-negative and Gram-positive panels* Beckman Coulter is pleased to announce the upcoming launch of 11 new Gram-negative and Gram-positive MicroScan panels. These include 7 new MicroScan MIC-only panels that provide extended ranges of antibiotic concentrations to assist in detection of antimicrobial resistance (AMR). MIC-only formats support laboratories utilizing alternative identification methods. Accurate MIC results in routine testing helps physicians choose and adapt patient therapies. This launch also includes new expert rules that align with the latest EUCAST and CLSI guidelines. Please contact your Sales Representative for additional information. Features and Benefits: Gram-negative panels 1. Lower dilutions of carbapenems, including EUCAST producing Enterobacteriaceae 2. Lower dilutions of levofloxacin and ciprofloxacin to detect fluoroquinolone resistance and to conform to new EUCAST breakpoints 3. Longer and lower dilutions of cefotaxime and ceftazidime both with and without clavulanic acid for detection and confirmation of ESBLs 4. Addition of trimethoprim 2-4 μg/ml to support EUCAST reporting guidelines Gram-positive panels 1. reporting for MRSA, MSSA, S. epidermidis and vancomycin-susceptible E. faecalis 2. Lower dilutions of ceftaroline and clindamycin for detection of emerging resistance 3. Lower dilutions of moxifloxacin to detect fluoroquinolone resistance and to conform to new EUCAST breakpoints 4. New formats designed specifically for testing of Staphylococci and Enterococci, maximizing antimicrobial agents reported by organism group 5. New formats maximize antimicrobial agents reported between the organism groups Enterobacteriaceae and nonfermentative Gram-negative bacilli 6. Updated Gram-negative identification database, including improved turnaround time for the identification of Acinetobacter Count on MicroScan for unmatched experience, expertise and selection. For over 35 years, MicroScan panels have provided gold-standard bacterial identification and susceptibility products to confront emerging resistance head on. MicroScan provides first-time accuracy with direct minimum inhibitory concentration (MIC) for trusted detection of emerging and critical antimicrobial resistance, helping you avoid delays associated with extra confirmatory testing, and real-time alerts to enable immediate action. * in development, pending CE compliance; not available for in vitro diagnostic use. Please contact your sales representative for more information.

NEW MICROSCAN GRAM-NEGATIVE MIC PANELS* Panel name EN 47 NF 50 EN 51 EN 52 MicroScan catalog number B1016-185 B1016-188 B1016-194 B1016-195 Reporting therapy CLSI CLSI or EUCAST EUCAST EUCAST Languages IT, Abbr. Antimicrobial agent µg/ml µg/ml µg/ml µg/ml Ak Amikacin 8-32 4-32 8-16 8-16 Aug Amoxicillin/K Clavulanate 8/4-16/8-2/1-8/4 4/2-32/16 Am Ampicillin 8-16 - 2-8 2-8 A/S Ampicillin/Sulbactam - 4/2-16/8 - - Azt Aztreonam 1-16 0.5-16 1-4 1-4 Cpe Cefepime 1-16 1-32 0.5-8 1-4 Cfe Cefixime - - - 0.5-1 Cft Cefotaxime 1-16 4-64 0.5-64 0.5-32 Cft/CA Cefotaxime/K Clavulanate 0.5/4-4/4-0.5/4-8/4 0.5/4-4/4 Cfx Cefoxitin 8-16 - 8-16 8-16 Cpd Cefpodoxime - - - 1 Caz Ceftazidime 1-16 1-32 0.5-64 0.5-32 Caz/CA Ceftazidime/K Clavulanate 0.25/4-4/4-0.25/4-8/4 0.25/4-4/4 Cax Ceftriaxone - - - - Crm Cefuroxime 4-16 - 4-8 4-8 C Chloramphenicol - - 8 - Cp Ciprofloxacin 0.12, 0.5-2 0.12-2 0.25-1 0.25-1 Cl Colistin 2-4 2-4 2-4 2-4 Dox Doxycycline - 4-8 - - Etp Ertapenem 0.25-1 - 0.12-1 0.12, 0.5-1 Fos Fosfomycin 32-64 32-64 32-64 32-64 Gm Gentamicin 2-8 1-8 2-4 2-4 Imp Imipenem 0.5-8 0.5-16 1-8 1-8 Lvx Levofloxacin 0.12, 1-4 0.5-4 0.12-1 0.5-1 Mec Mecillinam 8 - - 2, 8 Mer Meropenem 0.25-8 0.12-16 0.12, 1-32 0.12-8 Min Minocycline 4-8 2-8 - - NA Nalidixic Acid 16-16 16 Nt Netilmicin - 2-8 - - Fd Nitrofurantoin 32-64 - - 64 Nxn Norfloxacin 0.5-1 - - 0.5-1 Ofl Ofloxacin 2-4 - - - Pi Piperacillin 8-16, 64 8-64 4-16 4-16 P/T Piperacillin/Tazobactam 8/4-16/4, 64/4 8/4-64/4 4/4-16/4 4/4-16/4 Te Tetracycline - 2-8 - - Ti Ticarcillin - 8-64 8-16 8-16 Tim Ticarcillin/K Clavulanate - 16/2-64/2 - - Tgc Tigecycline 1-2 - 0.25-2 0.5-2 To Tobramycin 2-8 2-8 2-4 2-4 T Trimethoprim - - - 2-4 T/S Trimethoprim/Sulfamethoxazole 2/38-4/76 1/19-4/76 2/38-4/76 2/38-4/76 * In development, pending CE compliance; not available for in vitro diagnostic use. Please contact your sales representative for more information.

NEW MICROSCAN GRAM-NEGATIVE COMBO PANELS* Panel name Neg/Urine Combo 81 Neg Combo 82 Neg Combo 83 Neg Breakpoint Combo 50 MicroScan catalog number B1016-191 B1016-192 B1016-193 B1016-189 Reporting therapy EUCAST EUCAST EUCAST CLSI Languages IT, IT, IT, IT, Abbr. Antimicrobial agent µg/ml µg/ml µg/ml µg/ml Ak Amikacin 8-16 8-16 8-16 16-32 Aug Amoxicillin/K Clavulanate 8/4, 32/16 4/2-8/4 2/1, 8/4 8/4-16/8 Am Ampicillin 4-8 4-8 2, 8 8-16 A/S Ampicillin/Sulbactam - - - 8/4-16/8 Azt Aztreonam - 1-4 1, 4 4-16 Cfz Cefazolin - - - 2-4 Cpe Cefepime 1-8 1-4 1, 4-8 8-16 Cfe Cefixime 1 - - - Cft Cefotaxime 1-16 1-16 1-2, 16 1-2, 16 Cft/CA Cefotaxime/K Clavulanate 0.5/4-1/4, 4/4 0.5/4-1/4, 4/4 0.5/4, 4/4 0.5/4, 4/4 Cfx Cefoxitin 8-16 8-16 8 8-16 Caz Ceftazidime 1-16 1-8 1, 4-8 1, 4-16 Caz/CA Ceftazidime/K Clavulanate 0.25/4-0.5/4, 2/4 0.25/4, 2/4 0.25/4, 2/4 0.25/4, 2/4 Crm Cefuroxime 4-8 4-8 4-8 4-16 C Chloramphenicol - - 8 - Cp Ciprofloxacin 0.25-1 0.25-1 0.25-1 1-2 Cl Colistin 2-4 - 2-4 2-4 Etp Ertapenem 0.5-1 0.5-1 0.5-1 0.5-1 Fos Fosfomycin 32-64 32-64 32 - Gm Gentamicin 2-4 2-4 2-4 4-8 Imp Imipenem 1-8 1-8 1-8 1-8 Lvx Levofloxacin 0.5-1 0.5-2 0.5-1 2-4 Mec Mecillinam 8-8 - Mer Meropenem - 0.12, 2-8, 32 0.12, 2, 8 1-8 Mxf Moxifloxacin - - - 0.5-1 NA Nalidixic Acid 16 16 16 - Fd Nitrofurantoin 32-64 - 64 32-64 Nxn Norfloxacin 0.5-1 - - 4-8 Pi Piperacillin - - 4-16 - P/T Piperacillin/Tazobactam 8/4-16/4 8/4-16/4 4/4-16/4 16/4, 64/4 Te Tetracycline - - 8 - Ti Ticarcillin 8-16 - - - Tgc Tigecycline - 1-2 1-2 1-2 To Tobramycin 2-4 2-4 2-4 4-8 T Trimethoprim - - 2-4 - T/S Trimethoprim/Sulfamethoxazole 2/38-4/76 2/38-4/76 2/38-4/76 2/38 * In development, pending CE compliance; not available for in vitro diagnostic use. Please contact your sales representative for more information.

NEW MICROSCAN GRAM-POSITIVE MIC PANELS* Panel name Pos MIC STA 35 Pos MIC STA 36 Pos MIC E 37 MicroScan cathalog number B1016-181 B1016-182 B1016-183 Reporting therapy CLSI EUCAST CLSI or EUCAST Languages Abbr. Antimicrobial agent µg/ml µg/ml µg/ml Ak Amikacin 8-32 4-16 - Aug Amoxicillin/K Clavulanate 4/2-8/4-2/1-8/4 Am Ampicillin - - 1-8 Azi Azithromycin - 0.5-2 - CfxS Cefoxitin Screen 4 4 - Cpt Ceftaroline 0.5-2 0.12-2 - C Chloramphenicol - 8 8-16 Cp Ciprofloxacin 0.5-2 0.25-2 0.5-2 Cd Clindamycin 0.25-2 0.12-0.5 0.25-1 Dap Daptomycin 0.25-4 0.25-1 0.25-4 E Erythromycin 0.25-4 0.5-2 0.25-4 Fos Fosfomycin 4, 16-64 32 32-64 FA Fusidic Acid 2, 16 2, 16 - Gm Gentamicin 1-8 1-4 - GmS Gentamicin Synergy Screen - - 500 Imp Imipenem - - 2-8 ICd Inducible Clindamycin Test 4/0.5 4/0.5 - K Kanamycin 8-16 - Lvx Levofloxacin 0.5-4 0.5-4 1-4 Lin Lincomycin - 1-8 Lzd Linezolid 1-4 2-4 1-4 Min Minocycline 4-8 1 1-8 Mxf Moxifloxacin - 0.25-2 0.25-1 Mup Mupirocin 4-8, 256 4-8, 256 - Fd Nitrofurantoin 32-64 32-64 32-64 Ofl Ofloxacin 1 0.5-2 - Ox Oxacillin 0.25-2 0.25-2 - P Penicillin 0.03, 0.12-0.25, 2 0.03-0.12 0.06-8 Prs Pristinamycin - 0.5-2 0.5-2 Rif Rifampin 0.5-2 0.5-2 0.5-2 StS Streptomycin Synergy Screen - - 1000 Syn Synercid 0.5-2 0.5-2 1-4 Tei Teicoplanin 1-16 1-8 1-16 Te Tetracycline 1-8 1-2 1-8 Tgc Tigecycline 0.25-1 0.25-1 0.25-1 To Tobramycin 1-8 1-4 - T/S Trimethoprim/Sulfamethoxazole 1/19-4/76 1/19-4/76 0.25/4.75-2/38 Va Vancomycin 0.25-16 0.25-16 0.25-32 * In development, pending CE compliance; not available for in vitro diagnostic use. Please contact your sales representative for more information.

2017 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. www.beckmancoulter.com/contact BR 2017-001-MULTI-EN